
Conference Coverage
about 1 month ago
Stem Cell Engineering Reveals New Clues to Rebuilding Beta Cellsabout 1 month ago
New Research Points to Ways to Shield Beta Cells From DamageLatest Content

Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care

GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis

ICER Draft Flags High Cost of New Hypertension Drug Class

Medicare Accountable Care Organizations: Clinical Performance for Patients With Heart Failure

MDS/MPN Response Criteria Tied to Survival

Shorts










Center on Health Equity & Access
All News

Eli Lilly's investigational triple agonist is already fueling gray-market sales and a $1 trillion valuation narrative ahead of its 2027 FDA filing.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Following the Steward Health Care bankruptcy, Massachusetts law HB 5159 mandates rigorous oversight of for-profit health care transactions, providing a vital regulatory model for national replication.

A foundation model built on routine sleep studies outperformed the apnea-hypopnea index (AHI) in predicting mortality and cardiovascular risk in patients with sleep apnea.

Genetic ancestry was linked to differences in colorectal cancer (CRC) burden and age-specific risk, with implications for screening.

The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA.

Rising premiums and out-of-pocket costs top Americans' health care concerns across party lines, a Commonwealth Fund survey finds.

Although topical delgocitinib matched injectable dupilumab for CHE, real-world adherence could determine whether that holds outside clinical trials.

It also flagged persistent gaps in biomarker testing and the limits of cross-trial comparisons for treatment selection.

A narrative review links IL-17 signaling to metabolic syndrome and cardiovascular risk in psoriasis, though hard-outcome trial data remain limited.


























